We are live on ! Find out more

Caris Life Sciences

CAI

Market cap $8.35B

29.53 USD

-0.16

0.54%

At close Updated Oct 13, 4:00 PM EDT

Pre-market

After hours

29.53

0.00

0%

1 day

-0.54%

5 days

8.97%

1 month

13.36%

3 months

73.09%

6 months

54.36%

Year to date

9.45%

1 year

-2.41%

5 years

5.46%

10 years

5.46%

About: Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Employees: 1,846

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 29.4%

Neutral 58.8%

Negative 11.8%

Investors Business Daily

IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months

Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.

IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Grail's Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.

Investors Business Daily

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Wall Street projects the company turning a net profit of 12 cents a share this year.

Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look

Caris Life Sciences: Diagnostics Growth With Room To Run

Caris Life Sciences has an already established profiling business that provides revenue and cash flows for its expanding diagnostics portfolio. CAI reuses molecular data and clinical relationships, leveraging them into new tests that I believe should increase their shareholder value in the long run. CAI's Detect broadens its growth potential. However, we still need to see if their cash-pay adoption and marketing expenses pay off as intended.

Caris Life Sciences: Diagnostics Growth With Room To Run

Zacks Investment Research

Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?

Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide IRVING, Texas, Sept. 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner.

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer

Seven studies will be presented, including two mini oral presentations and a poster tour presentation IRVING, Texas, Sept. 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, South Korea.

Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer

Proactive Investors

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice

Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for pancreatic cancer. The research, published in npj Precision Oncology, describes the development and validation of the Caris AI Insights model using outcomes from patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.

Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies. The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature.

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial launch of Caris Detect reinforce the durability and breadth of CAI's growth drivers. Valuation remains attractive and CAI trades at a discount to peers, with a fair value estimate of $30 per share by 2028.

Caris Life Sciences: Guidance Raised, Valuation Still Attractive

See News Rankings

Price charts implemented using Lightweight Charts™